677 related articles for article (PubMed ID: 15596051)
41. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Blasco AJ; Llibre JM; Berenguer J; González-García J; Knobel H; Lozano F; Podzamczer D; Pulido F; Rivero A; Tuset M; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2015 Mar; 33(3):156-65. PubMed ID: 25175171
[TBL] [Abstract][Full Text] [Related]
42. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.
Mofenson LM;
MMWR Recomm Rep; 2002 Nov; 51(RR-18):1-38; quiz CE1-4. PubMed ID: 12489844
[TBL] [Abstract][Full Text] [Related]
43. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
44. Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan.
Ribera E; Martínez-Sesmero JM; Sánchez-Rubio J; Rubio R; Pasquau J; Poveda JL; Pérez-Mitru A; Roldán C; Hernández-Novoa B
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Mar; 36(3):157-164. PubMed ID: 28109551
[TBL] [Abstract][Full Text] [Related]
45. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
De Luca A; Hamers RL; Schapiro JM
J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
[TBL] [Abstract][Full Text] [Related]
46. [Infections with human immunodeficiency viruses. Part II: Antiretroviral drugs, therapeutic options, and diagnostics].
Stock I
Med Monatsschr Pharm; 2011 Jul; 34(7):234-44; quiz 245-6. PubMed ID: 21809598
[TBL] [Abstract][Full Text] [Related]
47. Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy.
Briand N; Mandelbrot L; Blanche S; Tubiana R; Faye A; Dollfus C; Le Chenadec J; Benhammou V; Rouzioux C; Warszawski J;
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):126-35. PubMed ID: 21436712
[TBL] [Abstract][Full Text] [Related]
48. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjechaj MJ;
Clin Trials; 2013; 10(1 Suppl):S5-S36. PubMed ID: 22547421
[TBL] [Abstract][Full Text] [Related]
49. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study.
Lee JS; Humes E; Hogan BC; Justice AC; Klein M; Gebo K; John Gill M; Silverberg MJ; Rebeiro P; Horberg M; Karris M; Rabkin C; Moore RD; Althoff KN;
Lancet HIV; 2022 Mar; 9 Suppl 1():S2. PubMed ID: 35304844
[TBL] [Abstract][Full Text] [Related]
50. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
51. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
[TBL] [Abstract][Full Text] [Related]
52. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
53. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
54. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
[TBL] [Abstract][Full Text] [Related]
55. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
56. [Consensus statement on assistance to women with human immunodeficiency virus infection in the health care sector. National AIDS Plan (PNS) and AIDS Study Group (GeSIDA)].
;
Enferm Infecc Microbiol Clin; 2014 Feb; 32(2):99.e1-99.e14. PubMed ID: 23896395
[TBL] [Abstract][Full Text] [Related]
57. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
Sungkanuparph S; Anekthananon T; Hiransuthikul N; Bowonwatanuwong C; Supparatpinyo K; Mootsikapun P; Chetchotisakd P; Kiertiburanakul S; Tansuphaswadikul S; Buppanharun W; Manosuthi W; Techasathit W; Ratanasuwan W; Tantisiriwat W; Suwanagool S; Leechawengwongs M; Ruxrungtham K;
J Med Assoc Thai; 2008 Dec; 91(12):1925-35. PubMed ID: 19133532
[TBL] [Abstract][Full Text] [Related]
58. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
59. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study.
Wolbers M; Bucher HC; Furrer H; Rickenbach M; Cavassini M; Weber R; Schmid P; Bernasconi E; Hirschel B; Battegay M;
HIV Med; 2008 Jul; 9(6):397-405. PubMed ID: 18410354
[TBL] [Abstract][Full Text] [Related]
60. Update on antiretroviral therapy.
Riordan A; Bugembe T
Arch Dis Child; 2009 Jan; 94(1):70-4. PubMed ID: 18838416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
